original ) (raw )Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa
Amos Korczyn
Clinical Neuropharmacology, 2000
View PDFchevron_right
Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy
Philip Lazarovici
Therapeutics and Clinical Risk Management, 2007
View PDFchevron_right
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Anna Zecchinelli
Journal of neurology, 2017
View PDFchevron_right
Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
Christoph Schrader
Journal of Neural Transmission, 2023
View PDFchevron_right
Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease
Rainer Apfel
European Journal of Neurology, 2010
View PDFchevron_right
Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
Michele Pistacchi
Neurology and Therapy, 2013
View PDFchevron_right
Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson's disease
David Guay
The American Journal of Geriatric Pharmacotherapy, 2006
View PDFchevron_right
Pharmacotherapy for Parkinson's disease
Jack Chen
Pharmacotherapy, 2007
View PDFchevron_right
A Controlled Trial of Rasagiline in Early Parkinson Disease
C Allen
Archives of Neurology, 2002
View PDFchevron_right
Randomized, Controlled Trial of Rasagiline as an Add-on to Dopamine Agonists in Parkinson's Disease
Eli Eyal
View PDFchevron_right
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
Wolfgang Jost
Journal of Neural Transmission, 2022
View PDFchevron_right
Rapid onset of efficacy of rasagiline in early Parkinson’s disease
Luciana Baroni
Neurological Sciences, 2013
View PDFchevron_right
Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
Manal Ali
Frontiers in Aging Neuroscience, 2014
View PDFchevron_right
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
Peter Lewitt
Movement Disorders, 2004
View PDFchevron_right
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability
Eli Eyal
2015
View PDFchevron_right
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
Eli Eyal
JAMA Neurology, 2015
View PDFchevron_right
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack Chen
Clinical therapeutics, 2007
View PDFchevron_right
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
Benzi Kluger
Movement Disorders, 2015
View PDFchevron_right
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
F. Stocchi
Movement Disorders, 2008
View PDFchevron_right
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Paul Feigin
The New England Journal of Medicine, 2009
View PDFchevron_right
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
Teresa Nunes
Journal of the Neurological Sciences, 2013
View PDFchevron_right
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Paul Feigin
The Lancet Neurology, 2011
View PDFchevron_right
Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
giuseppe di iorio
Neuropsychiatric Disease and Treatment, 2016
View PDFchevron_right
Letter Adjunctive Therapies in Parkinson JAMA
Anil Gumber
View PDFchevron_right
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Peter Lewitt
The Lancet Neurology, 2019
View PDFchevron_right
Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease
Richard Dewey
Progress in medicinal chemistry, 1984
View PDFchevron_right
Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease
Robert Rubens
Clinical Neuropharmacology, 2018
View PDFchevron_right
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy
Robert Hawker
JAMA Neurology
View PDFchevron_right